{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T17:05:12Z","timestamp":1789578312152,"version":"build-2803163510"},"reference-count":8,"publisher":"Elsevier BV","issue":"4","license":[{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,8,1]],"date-time":"2026-08-01T00:00:00Z","timestamp":1785542400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","euoncology.europeanurology.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["European Urology Oncology"],"published-print":{"date-parts":[[2026,8]]},"DOI":"10.1016\/j.euo.2026.04.014","type":"journal-article","created":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:48:31Z","timestamp":1778248111000},"page":"758-760","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"title":["Metformin in Prostate Cancer: A Negative Repurposing Story Across the Disease Continuum"],"prefix":"10.1016","volume":"9","author":[{"given":"Dries","family":"Develtere","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-6772-915X","authenticated-orcid":false,"given":"Ga\u00ebtan","family":"Devos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.euo.2026.04.014_b0005","doi-asserted-by":"crossref","unstructured":"Gillessen S, Gobat K, Cathomas R, et al. Enzalutamide plus metformin versus enzalutamide alone in metastatic castration-resistant prostate cancer: a randomized Phase 2 trial (SAKK 08\/14). Eur Urol Oncol 2026;9:822\u2013832. https:\/\/doi.org\/10.1016\/J.EUO.2026.03.001.","DOI":"10.1016\/j.euo.2026.03.001"},{"key":"10.1016\/j.euo.2026.04.014_b0010","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2025.118507","article-title":"From basics to clinics: new opportunities for metformin in tumor metabolic intervention and treatment","volume":"191","author":"Lv","year":"2025","journal-title":"Biomed Pharmacother"},{"key":"10.1016\/j.euo.2026.04.014_b0015","first-page":"57","article-title":"Metformin in cancer prevention and therapy","volume":"2","author":"Kasznicki","year":"2014","journal-title":"Ann Transl Med"},{"key":"10.1016\/j.euo.2026.04.014_b0020","doi-asserted-by":"crossref","first-page":"2218","DOI":"10.1038\/s41598-018-38285-w","article-title":"The effect of metformin therapy on incidence and prognosis in prostate cancer: a systematic review and meta-analysis","volume":"9","author":"He","year":"2019","journal-title":"Sci Rep"},{"key":"10.1016\/j.euo.2026.04.014_b0025","doi-asserted-by":"crossref","first-page":"831.e1","DOI":"10.1016\/j.urolonc.2021.05.020","article-title":"Repurposing metformin as anticancer drug: randomized controlled trial in advanced prostate cancer (MANSMED)","volume":"39","author":"Alghandour","year":"2021","journal-title":"Urol Oncol"},{"key":"10.1016\/j.euo.2026.04.014_b0030","doi-asserted-by":"crossref","first-page":"3662","DOI":"10.1200\/JCO-25-01070","article-title":"Metformin active surveillance trial in low-risk prostate cancer","volume":"43","author":"Fleshner","year":"2025","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.euo.2026.04.014_b0035","doi-asserted-by":"crossref","first-page":"1018","DOI":"10.1016\/S1470-2045(25)00231-1","article-title":"Metformin for patients with metastatic prostate cancer starting androgen deprivation therapy: a randomised phase 3 trial of the STAMPEDE platform protocol","volume":"26","author":"Gillessen","year":"2025","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.euo.2026.04.014_b0040","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1016\/j.clgc.2021.08.008","article-title":"TAXOMET: a French prospective multicentric randomized Phase II study of docetaxel plus metformin versus docetaxel plus placebo in metastatic castration-resistant prostate cancer","volume":"19","author":"Pujalte Martin","year":"2021","journal-title":"Clin Genitourin Cancer"}],"container-title":["European Urology Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001239?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2588931126001239?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T16:46:01Z","timestamp":1789577161000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2588931126001239"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8]]},"references-count":8,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,8]]}},"alternative-id":["S2588931126001239"],"URL":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.014","relation":{},"ISSN":["2588-9311"],"issn-type":[{"value":"2588-9311","type":"print"}],"subject":[],"published":{"date-parts":[[2026,8]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Metformin in Prostate Cancer: A Negative Repurposing Story Across the Disease Continuum","name":"articletitle","label":"Article Title"},{"value":"European Urology Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.euo.2026.04.014","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"simple-article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Association of Urology. Published by Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}]}}